1) 33 providing data on risk and protective factors and 18 providing only prevalence d |
2) EPAs (n = 11,37.9%); (3) examining the factors and barriers that influence the im |
3) understanding of the link between social factors and cerebrovascular disease will b |
4) Objective: To identify patient-related factors and characteristics of PILs that c |
5) gulatory programs involving transcription factors and chromatin modulators. |
6) iodontal diseases and COVID-19; (ii) risk factors and comorbidities common to period |
7) e delivery, including addressing upstream factors and comorbidities impacting skin h |
8) in children and highlights important risk factors and comorbidities. |
9) arable clinical evidence in terms of risk factors and complications, challenges pres |
10) heir expression of specific transcription factors and cytokines1. |
11) o understand the nature of the major risk factors and design features of a safe and |
12) the association between built environment factors and dietary intake, physical activ |
13) the association between built environment factors and dietary intake, physical activ |
14) iations between physical or psychological factors and either walking capacity, gait |
15) on facilitators (category 2: motivational factors and exercising effects). |
16) f the categories of the psychosocial risk factors and hazards affecting HCWs during |
17) Overall, the key diet-related risk factors and health outcomes were modeled, |
18) We discuss the challenges of contextual factors and highlight innovation needs. |
19) ions between several colostrum management factors and immunological colostrum qualit |
20) to food insecurity, but the contributing factors and impacts of this issue were ins |
21) iations between physical or psychological factors and impaired walking capacity in p |
22) arch has been undertaken to identify risk factors and intervention methods to decrea |
23) hart all available literature on the risk factors and interventions associated with |
24) The risk factors and interventions pertaining to ta |
25) Poor socioeconomic factors and low educational background wer |
26) /mTOR pathways and supresses inflammatory factors and mediators such as IL-1β, IL-6 |
27) niform framework that specifies different factors and metrics for the evaluation is |
28) Strengthening protective factors and minimizing the impact of risk |
29) data provide further insight into genetic factors and pathways involved in PTSD, as |
30) be used to improve understandings of risk factors and pathways. |
31) ginating from both patient/family-related factors and physician/health system compon |
32) In this review, we discuss the GIT factors and physicochemical and biological |
33) combined stressor exposures and personal factors and risk to foster methods for occ |
|